Pertuzumab

In the current field of commercial products, PD-1 drugs in the field of solid tumor treatment occupy a dominant position, at the same time, a variety of other therapies also show their unique advantages. The interwoven development of these therapies has together written a magnificent chapter in the long struggle against cancer. As the market leader, K drug not only dominates the field of oncology drugs, but also ranks first in the global drug sales list in the first half of 2024. It has been ten years since 2014, when the US Food and Drug Administration (FDA) accelerated approval of its melanoma indication. As of June 17, 2024, 40 indications have been approved for drug K. The O drug, followed by the approval of the market in 2015, also takes melanoma as a starting point, and continues to expand in the field of tumor treatment.   PD-1 therapy represents a generational leap in oncology drug research by activating T cell immune processes to fight cancer cells. The therapy has a wide range of combined application potential, and the combination of chemotherapy, antibody drug conjugate (ADC), small molecule targeting drugs and even new Chinese medicines has brought a new idea for cancer treatment.   In the field of hematoma treatment, the CD38 monoclonal antibody Darzalex has changed the landscape of myeloma treatment. The drug was launched in late 2015, becoming the world's first approved monoclonal antibody for CD38. Its treatment regimen has advanced from the back line to the front line, rapidly covering multiple myeloma treatment from the fourth line to the first line, largely replacing the traditional small molecule drug lenalidomide, which is No.6 Revlimid in the list.   Johnson & Johnson's BTK inhibitor ibrutinib, as a pioneer of small molecule inhibitors, is also epoch-making. At the same time, Zeebutinib, a subsidiary of China's "first innovative drug brother", has also joined the competition. Patents on both drugs are about to expire, with ibrutinib's compound patent set to expire in 2026 and Darzalex's patent set to expire in 2029. Johnson & Johnson is already laying out the next generation of therapies, breaking new ground in hematoma with Legend Biotech's CAR-T therapy.   For solid tumors, in addition to PD-1 monoclonal antibody, drugs targeting tumor cell targets are highly targeted and may be studied in depth on specific several solid tumors. Most of today's sales leaders are derived from pipeline layouts from 10 years ago, so you can see many of the popular monoclonal antibody layouts at the time, which are aligned with the current cutting edge dual antibody and ADC drugs.   As a third-generation small molecule drug targeting EGFR, Tagrisso (Ohitinib) has solved many problems of the first two generations of drugs and rapidly promoted the number of treatment lines, and has become a first-line drug for non-small cell lung cancer (NSCLC). Current research and development is focused on addressing resistance to ocitinib, which is often used as a control in Phase III clinical trials. The recently launched deuterated small molecule drug from Homekonil and the recently announced EGFR/c-MET dual antibody from Johnson & Johnson address this challenge.   Xtandi is an outstanding representative of the era of small molecule medicine. Since it was first approved in 2012, it has been used to treat prostate cancer because it specifically blocks the function of androgens binding to receptors. The classic treatment is in combination with leprerelin, which is androgen deprivation therapy (ADT). At present, prostate cancer indications have become an important platform for RDC drugs. Breast cancer and prostate cancer, as gender-specific cancers, are special in men and women. Breast cancer has the second highest incidence in women, and HER2 is an important target of breast cancer. Clinically, breast cancer is usually divided into three types: zero HER2 expression, low HER2 expression and HER2 positive expression. If the HER2 target of breast cancer patients is positive, treatment options will be more abundant, among which Perjeta (Pertuzumab), as an outstanding representative of targeted drugs, is used in combination with trastuzumab to jointly act on the HER2 target. It is worth noting that the U.S. patent for trastuzumab expired in 2019, and the current market competition is mainly focused on biosimilars.   Verzenio (Abesili), as another important drug in the treatment of breast cancer, is a small molecule kinase inhibitor that affects the cell cycle and cancer cell proliferation by inhibiting CDK 4/6 activity. However, the drug is mainly suitable for patients with hormone receptor (HR) positive breast cancer, and has significant efficacy for types of breast cancer that are HR positive but HER2 negative.   The current sales of leading cancer drugs represent the wisdom of the previous generation of developers, and build a complete system of cancer treatment. Just as contemporary developers are tackling challenges in the field of ADC, multi-antibody, CAR-T and other therapies, the efforts and dedication of each generation ultimately translate into longer survival of cancer patients.   In the HER2 target segment, DS-8201 is an emerging force in ADC drugs, with sales reaching $1.772 billion in the first half of 2024, a significant increase from $1.2 billion last year. The drug is not limited to breast cancer, receiving FDA approval for gastric cancer in January 2021, and its development pipeline also includes non-small cell lung cancer and colorectal cancer.   Targeting the breast cancer indication, Trodelvy, the trop2 ADC, offers new therapeutic promise for patients with triple-negative breast cancer. The drug received accelerated FDA approval in 2020 with Phase I/II trial results, making trop2 ADC a hot target in the ADC field after HER2, on par with nectin-4.   In the field of hematoma treatment, CAR-T therapy has completely changed the treatment landscape of multiple myeloma. At present, the research and development of CAR-T therapy is focusing on autoimmune diseases and solid tumors, which is expected to bring new treatment hope for glioblastoma, a stubborn cancer. The current treatment for this intracranial tumor is still stuck in the chemotherapy stage of many years ago, although there have been advances in electric field therapy in recent years.   Legend Biotech's CAR-T drug, Cedarkeolenxel, is expected to become a new sales star in the coming years, and the key is approval of the first-line treatment. If the acquisition news is confirmed, it will likely have a positive impact on the advancement of the Sidagiolencel indication.   One of the development directions of PD-1 is dual antibody. As a representative enterprise, Kangfang Biologic's AK-104 (PD-1/CTLA-4 double antibody) and AK112 (PD-1/VEGF double antibody) are both innovative drugs on the market. AK-104 is the first marketed PD-1/CTLA-4 dual antibody, and AK112 is the first marketed PD-1/VEGF dual antibody.   Product Name Compound Indication Company Sales (100 Million CNY) Keytruda PD-1 Melanoma Merck & Co. 142.17 Darzalex CD38 Multiple Myeloma Janssen 55.7 Opdivo PD-1 Melanoma BMS 44.65 Imbruvica BTK Blood Cancer AbbVie/Johnson & Johnson 32.25 Tagrisso EGFR NSCLC AstraZeneca 32.03 Revlimid TNF-α Multiple Myeloma BMS 30.22 Xtandi AR Prostate Cancer Pfizer/Astellas 28.3 Verzenio CDK4/6 Breast Cancer Eli Lilly 23.82 Perjeta HER2 Breast Cancer Roche 23.17 Tecentriq PD-L1 Lung Cancer Roche 23.08

As major multinational corporations (MNC) report their financial results for the second quarter of 2024, pharmaceutical industry leaders such as Astrazeneca, Roche, Sanofi, Johnson & Johnson and Novartis have announced their financial results for the first half of 2024 (H1). As of August 6, according to the operating income data of the first half of the year, the ranking of the top ten enterprises in the global pharmaceutical industry has been settled, and the specific ranking is as follows: Quarterly and Half-Yearly Revenue and Year-Over-Year Growth Rate Chart for the Second Quarter and Full Year 2024 Rank Company 2024 Q2 Revenue (Billion USD) YoY Growth 2024 H1 Revenue (Billion USD) YoY Growth 1 Johnson & Johnson 224.5 4.3% 438 3.3% 2 Roche 178.19 13.9% 337.19 5.0% 3 Merck 161.12 7.2% 318.87 8.0% 4 Pfizer 132 2.0% 281.62 -11.0% 5 AbbVie 144.62 4.3% 267.72 3.7% 6 AstraZeneca 129.38 13.3% 256.17 18.0% 7 Novartis 125.1 11.0% 243 11.0% 8 Bristol-Myers Squibb 122.01 9.0% 240.66 7.0% 9 Sanofi 117.22 10.2% 230.20 8.4% 10 GlaxoSmithKline 100.38 13.0% 194.12 12.0%   With the gradual fading of the novel coronavirus epidemic in 2023, the revenue pattern of the global large pharmaceutical companies has ushered in a new round of change. Entering 2024, the impact of the epidemic on business operations has significantly weakened, and pharmaceutical companies have gradually returned to the normal development track. From the performance point of view, in the first half of 2024, in addition to Pfizer, the revenue of the remaining nine pharmaceutical companies generally showed an increase.   Against this backdrop, Johnson & Johnson has solidified its position as the top global pharmaceutical and medical device company in terms of revenue. According to the financial data for the first half of 2024, Johnson & Johnson's overall revenue reached $43.83 billion, an increase of 3.3%. From the perspective of treatment segment segmentation, the tumor segment is particularly strong, and its revenue has surpassed the autoimmune diseases segment to become the largest revenue contribution of Johnson & Johnson. Specifically, revenue from the oncology segment reached $5.09 billion in the second quarter, up 15.7% year over year; In the autoimmune diseases segment, revenue in the same period was $4.722 billion, a growth rate of only 5%.   In terms of product lines, Darzalex in oncology, with its $5.57 billion in sales, successfully surpassed Stelara in autoimmune diseases ($5.536 billion in sales) to become the top-selling product in the first half of 2024. In addition, two new oncology drugs, BCMA CAR-T therapy Carvykti and dual antibody product Tecvayli, also showed strong growth momentum, with sales reaching $343 million and $268 million, respectively, with year-on-year growth rates of 81.5% and 70.2%.   In order to further strengthen its competitiveness in the field of oncology and immunization, Johnson & Johnson continues to increase investment in innovative drugs. In the first half of 2024, J&J completed a number of important acquisitions. Among them, the $2 billion acquisition of AmbrxBiopharma brought several ADC pipelines to the company; The $850 million acquisition of Proteologix and the $1.25 billion acquisition of a subsidiary of NumabTherapeutics further strengthen the company's portfolio of dual antibody products in the field of autoimmune diseases.   Roche showed solid growth in the first half of 2024, with total revenues of CHF 29.848 billion (US $33.719 billion), up 5% year-on-year. Among them, the pharmaceutical business, as the core driver, contributed 22.637 billion Swiss francs (about $25.573 billion) in revenue, and China revenue achieved double-digit growth to reach 1.609 billion Swiss francs (about $1.818 billion).   In pharmaceuticals, the oncology segment continued to play a leading role, contributing 9.619 billion Swiss francs ($10.867 billion), or 42.5% of total revenue, to Roche, which remained at 4% despite a slight slowdown in year-on-year growth. In contrast, the ophthalmology business showed strong growth with revenues of CHF 1.891 billion, up 54% year on year, and although it currently accounts for only 8.4% of total revenues, its potential cannot be ignored.   Specific to the product level, the ophthalmological double antibody Vabysmo (Pharisimumab) performance is particularly outstanding, the first half of the sales revenue of up to 1.794 billion Swiss francs (about 2.027 billion US dollars), an increase of 93%, almost doubled, successfully ranked among Roche's top 5 best-selling drugs. In addition, Ocrevus (Orizumab), Hemlibra (Emetzizumab), Evrysdi (Rispran), Phesgo (Trastuzumab + pertuzumab), Polivy (Vipostuzumab), Xolair (Omazumab), Alecensa (Aletinib) and other drugs also remained strong Growth trend.   On the other hand, Merck also achieved impressive results in the first half of 2024. The company's total revenue reached $31.887 billion, an increase of 8%, and pharmaceutical revenue reached $28.415 billion, an increase of 9%. Revenue in the second quarter was $16.1 billion, up 7 percent from a year earlier. This increase was mainly due to the excellent performance of K-drug (Pabolizumab) and HPV vaccine.   As a star product of Merck, K drug sales reached 14.217 billion US dollars in the first half of this year, achieving a double-digit high growth of 18%, and is expected to break through the 30 billion US dollars mark for the whole year. At the same time, HPV vaccines also maintained a stable sales performance, Gardasil/Gardasil 9 sales reached $4.727 billion, an increase of 7%.   In addition, the company's oncology products such as Welireg (HIF-2α inhibitor) and Reblozyl (Rottsip), as well as the anti-cytomegalovirus infection drug Prevymis (Lytamovir) and 15-valent pneumococcal vaccine Vaxneuvance, also achieved double-digit or higher growth.   However, it is worth noting that Merck's main revenue is still highly dependent on K drugs and HPV vaccines. Among them, K drug sales accounted for nearly half of the company's total revenue. Although K-drug is still in a period of rapid growth, its patent will expire in 2028, when it will face the risk of declining sales. At the same time, the HPV vaccine market is increasingly competitive, and Merck's HPV vaccine sector revenue is not indestructible.   As a result, MSD is actively pursuing a second growth curve. Since the beginning of this year, the company has continuously introduced new potential products and pipelines through acquisitions, including pneumonia conjugate vaccine, the new drug Sotatercept for pulmonary hypertension, a new generation of RSV neutralizing antibodies, TL1A antibodies, and neoantigen mRNA vaccines, with a view to achieving more diversified revenue sources in the future.   Among the world's top 10 multinational pharmaceutical companies, Pfizer has been the most affected by the COVID-19 pandemic. In 2023, due to the sharp decline in sales of new coronavirus vaccine Comirnaty and anti-new coronavirus drug Paxlovid, the company failed to continue the brilliant performance of over 100 billion dollars in 2022, not only lost the top position in the industry, but also withdrew from the top three ranks. Entering 2024, although the first half of the revenue decline is still as high as 11%, showing that the company has not completely rid of the negative impact of the fading of the new coronavirus dividend, but the second quarter performance has shown signs of recovery. Financial data show that in the first half of 2024, the company's total revenue was 28.162 billion US dollars, down 11% year-on-year; In the second quarter, revenue reached $13.2 billion, up 2% from the same period last year and exceeding market analysts' expectations ($12.96 billion). If the contribution of COVID-19 vaccines and oral COVID-19 drugs is not included, the revenue growth in the second quarter was more significant, reaching 14%, which is the first time since the global coronavirus epidemic gradually eased in the fourth quarter of 2022, Pfizer achieved positive quarterly revenue growth, marking the company has adjusted to a good state and embarked on a new journey.   From the perspective of business structure, in the first half of 2024, the revenue of COVID-19 product Paxlovid was 2.286 billion US dollars, down 46% year-on-year; Comirnaty's revenue was $548 million, down 88% year over year. Despite the continued decline in revenue from COVID-19 products, the company's oncology business has achieved rapid growth, reaching $7.505 billion in revenue in the first half of the year, up 23% year-on-year. Among them, the breast cancer blockbuster CDK4/6 inhibitor Ibrance (Pipercilil), despite a slight decline in sales (-8%), still topped oncology drug sales with $2.184 billion in revenue. Androgen receptor signaling inhibitor Xtandi (Enzaluamide) and third-generation ALK inhibitor Lorbrena (Loratinib) also saw growth of 20% and 46%, respectively, with revenues of $913 million and $332 million, respectively.   In addition, ADCs such as Vyndaqel (chlorobenzolic acid), Eliquis (Apoxaban) and Nurtec ODT/Vydura, which were acquired through the Seagen acquisition, also began to contribute to the company's revenue. Abbvie also showed solid growth in the first half of 2024, with total revenue of $26.772 billion, up 3.7% year-on-year. In terms of therapeutic areas, autoimmune diseases, neuroscience, and oncology were the three pillars of the company's revenue, generating $12.342 billion (+0.6%), $4.127 billion (+15.6%), and $3.177 billion (+11%), respectively.   In the autoimmune diseases segment, although Humira (Adalimumab) has failed to reverse the downward trend in performance, with a decline of about 32% to $5.084 billion, full-year revenue is expected to fall below the $10 billion mark. However, the company's two star products in the field, Skyrizi (Lisencizumab) and Rinvoq (Upatinib), have maintained strong growth momentum, achieving revenue of $4.735 billion (+46.6%) and $2.523 billion (+60.4%), respectively, of which Skyrizi is expected to break the $10 billion revenue mark by the end of the year. In the oncology segment, Imbruvica continued to lose market share, with first-half revenue down 6.4% year-on-year to $1.671 billion; Venclexta, on the other hand, maintained steady growth, with first-half sales of $1.251 billion (+16%). In addition, the new blood cancer product CD3/CD20 dual antibody Epkinly since the FDA approved the market in May last year, sales have also doubled, from $31 million in the first half of 2023 to $63 million in the first half of this year. At the same time, the FRα ADC drug Elahere (Somituximab) acquired by the company in the acquisition of ImmunoGen late last year also contributed $192 million to the company's revenue in six months.   In the neuroscience segment, with the exception of Duodopa, a drug for Parkinson's disease, which showed negative growth, all products achieved steady growth. Although Qulipta's sales volume is not large ($281 million in revenue in the first half of the year), the growth rate is as high as 73.2%, becoming the fastest growing product in the field. Other products such as Ubrelvy, Botox Therapeutics and Vraylar also saw varying degrees of growth. Looking ahead, as AbbVie's pipeline in neuroscience continues to advance and its layout is optimized, the company is expected to continue to expand its market advantage in this field.   Novartis continues to deepen its commitment to nuclear medicine and invests in small nucleic acids and gene therapy. In the first half of 2024, Novartis achieved total revenue of $24.3 billion, an increase of 11%, of which sales in the China market reached $2.1 billion, an increase of 29%.   In the therapeutics segment, Novartis is showing strong growth. Oncology revenue reached $6.984 billion, up 14% year-over-year; Cardiovascular/renal metabolism revenue of $4.111 billion, up 37% year-over-year; Immunization revenue was $4.403 billion, up 21% year on year; Revenue in the neuroscience segment was $2.234 billion, up 39% from a year earlier.   Within these areas, several of Novartis's core products performed well, such as Entresto (sacubactril valsartan) revenue of $3.777 billion, up 30% year-over-year; Kesimpta (Oftolumab) revenue of $1.436 billion, an increase of 64%; Cosentyx revenue of $2.852 billion, up 21% year-over-year; Kisqali (Ribosili) revenue of $1.344 billion, an increase of 48%.   In addition, Novartis's layout in the field of nuclear drugs has also achieved significant results. In the first half of the year, Pluvicto and Lutathera generated revenue of $655 million (+45%) and $344 million (+16%), respectively, for a combined revenue of nearly $1 billion. Meanwhile, sales of Leqvio, a long-acting PCSK9 siRNA lipd-lowering drug, reached $333 million, up 135% year-over-year, making it Novartis' fastest growing new drug category. Gene therapy products also performed well, with Zolgensma, which treats spinal muscular atrophy (SMA), reporting first-half revenue of $644 million, up 6 percent year-on-year.   It is worth noting that Novartis has shown a unique vision in product development and M&A strategy. Unlike other multinational pharmaceutical companies (MNC), Novartis's products and research pipeline are less involved in ADC, PD-1, GLP-1 and other hot tracks. Instead, Novartis prefers to focus on the development of cutting-edge technologies and innovative therapies, such as nuclear drugs, small nucleic acids, cell and gene therapies (CGT). Although the combined revenue of these emerging areas is still less than 10% of total revenue, Novartis's future development prospects will be broader as the market matures in the future.   In addition, the top 10 MNCS such as Astrazeneca, Sanofi, GlaxoSmithKline, Bristol-Myers Squibb also achieved positive revenue growth in the first half of 2024. With the intensification of market competition, each MNC is actively adjusting its strategy, some grasp the hot spots of The Times to expand the advantages of the field, some choose to avoid homogenized competition, and some focus on the core business by cutting off non-core assets. All these efforts are in order to stand out in the fierce market competition, looking forward to the second half of the MNC can continue to bring wonderful performance.